Nivolumab-Induced Rapid Tumor Remission of Pulmonary Adenocarcinoma
- *Corresponding Author:
- Falkenstern-Ge RF
Division of Pulmonology, Klinik Schillerhoehe
Center for Pulmonology and Thoracic Surgery
Teaching Hospital of the University of Tuebingen
Solitude Str. 18, 70839 Stuttgart-Gerlingen
E-mail: [email protected]
Received Date: December 20, 2016 Accepted Date: February 21, 2017 Published Date:February 26, 2017
Citation: Falkenstern-Ge RF, Kimmich M, Wohlleber M, Bode-Erdmann S, Friedel G, et al. (2017) Nivolumab-Induced Rapid Tumor Remission of Pulmonary Adenocarcinoma. Oncol Cancer Case Rep 3: 126. doi: 10.4172/2471-8556.1000126
Copyright: © 2017 Falkenstern-Ge RF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. Nivolumab received FDA approval for the treatment of melanoma in December 2014. On 24 April 2015, the Committee for Medical Products for Human Use of the European Medicine Agency recommended approval of Nivolumab for metastatic melanoma as a monotherapy. In March 2015, the US FDA approved it for the treatment of squamous non-small cell lung cancer. This case reports about a patient with metastatical pulmonary adenocarcinoma who benefited from the therapy with nivolumab. Already after 10 weeks of treatment with nivolumab, we registered rapid tumor remission.